Here is a structured market overview of the Inflammatory Bowel Disease (IBD) Treatment Market with company references and quantified insights:

Inflammatory Bowel Disease (IBD) Treatment Market

Market Size & Key Companies

• Market size: USD 20.74 billion (2023) → projected USD 27.73 billion by 2030 (CAGR 3.8%)
• Key companies:
  • AbbVie Inc. (Humira, Skyrizi)
  • Johnson & Johnson Services, Inc.
  • Takeda Pharmaceutical Company Limited
  • Pfizer Inc.
  • Biogen
  • Novartis AG
  • Eli Lilly and Company
  • UCB S.A.
  • Celltrion Inc.
  • Merck & Co., Inc.

Recent Developments

• AbbVie received regulatory approvals for Skyrizi (UC & Crohn’s) expanding biologics portfolio.
• Eli Lilly acquired Morphic Holding (~$3.2B) to strengthen oral IBD pipeline.
• Pfizer launched Velsipity (etrasimod) – oral S1P modulator for ulcerative colitis.
• Increased biosimilar launches (e.g., Hadlima – Humira biosimilar) improving affordability.

Drivers

• Rising prevalence of Crohn’s disease & ulcerative colitis (~5 million UC cases globally)
• Strong adoption of biologics (≈52% market share in 2024)
• Growing approvals of JAK inhibitors & S1P modulators
• Increasing diagnosis rates and awareness

https://www.thebrainyinsights.com/report/inflammatory-bowel-disease-treatment-market-12607

Restraints

• High cost of biologic therapies limiting access
• Stringent regulatory approvals delaying product launches
• Availability of alternative treatments (surgery, diet, probiotics)
• Patent expiries → pricing pressure due to biosimilars

Regional Segmentation Analysis

• North America
  • Largest share: 57.59% (2023)
  • Driven by strong pharma presence (AbbVie, Pfizer, J&J)
• Europe
  • Mature market with high biologics adoption
• Asia-Pacific
  • Fastest growing region due to rising healthcare spending and patient pool
• Latin America & MEA
  • Emerging markets with improving access

Emerging Trends

• Shift toward targeted therapies & precision medicine
• Rapid growth of biosimilars and monoclonal antibodies
• Development of oral biologics alternatives
• Integration of AI in clinical trials & diagnosis
• Expansion of online pharmacies & self-administered injectables

Top Use Cases

• Treatment of:
  • Crohn’s disease (≈60.6% market share)
  • Ulcerative colitis
• Drug classes:
  • TNF inhibitors (≈36.9% share)
  • Immunosuppressants
  • Corticosteroids
  • Biologics & biosimilars
• End users:
  • Hospitals
  • Specialty clinics
  • Homecare (self-injectables)

Major Challenges

• Long-term safety concerns of immunosuppressants
• Lack of permanent cure (chronic disease management)
• Patient variability in drug response
• High treatment discontinuation rates
• Complex clinical trial requirements

Attractive Opportunities

• Expansion of biosimilars market (cost reduction)
• Development of oral therapies (non-injectable biologics)
• Growth in Asia-Pacific healthcare infrastructure
• Personalized medicine & biomarker-driven therapies
• Strategic collaborations & M&A among pharma companies

Key Factors of Market Expansion

• Increasing R&D investments in biologics & novel drugs
• Strong pipeline of advanced therapies (JAK, S1P, monoclonal antibodies)
• Rising healthcare expenditure globally
• Improved reimbursement policies in developed markets
• Growth of telemedicine & digital healthcare platforms

If you want, I can also provide a competitive benchmarking (market share %, revenue by company, pipeline drugs) or a Porter’s Five Forces analysis for this market.